港股异动 | 锦欣生殖涨近5% 接连获纳入恒生综合大中型股指数和港股通名单
格隆汇9月12日丨锦欣生殖(1951.HK)涨近5%,报11.46港元,成交6503万港元,总市值272.8亿港元。上交所和深交所上周五分别发公告,宣布今年6月底上市的锦欣生殖获调入港股通名单,当日生效。此前,锦欣生殖已经获纳入恒生综合大中型股指数。2019上半年,公司共实现收益7.91亿元,同比增长92.09%;毛利3.81亿元,同比增长100.31%;除税前利润2.44亿元,同比增长72%,净利润1.78亿元,同比增长64.8%。在2019年半年报中锦欣生殖还披露,公司将继续在成都、深圳下属或合作医院投资遗传和生殖免疫学相关的基础研究以及成功率较高的胚胎生理外观研究,并积极面向海内外科研机构寻求技术合作,以改善IVF成功率的新方法,促进新技术的临床转化、拓展服务内容。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.